Literature DB >> 8707107

Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.

R H Holloway1, J Dent, F Narielvala, A M Mackinnon.   

Abstract

BACKGROUND/AIMS: Reducing oesophageal acid exposure by suppressing acid secretion with omeprazole is highly effective in healing reflux oesophagitis. Some patients with severe oesophagitis, fail to heal and whether this results from inadequate acid suppression or other factors is unclear. The aim of this study, was to investigate the relation between oesophageal acid exposure and healing in patients with severe reflux oesophagitis treated with omeprazole.
METHODS: Sixty one patients with grade 3 or 4 ulcerative oesophagitis were treated for eight weeks with omeprazole 20 mg every morning. Those patients unhealed at eight weeks were treated with 40 mg every morning for a further eight weeks. Endoscopy and 24 hour oesophageal pH monitoring were performed before treatment and at the end of each treatment phase while receiving treatment.
RESULTS: Thirty per cent of patients failed to heal with the 20 mg dose. Unhealed patients had greater total 24 hour oesophageal acid exposure before treatment, and while receiving treatment also had greater acid exposure and a smaller reduction in acid exposure than did patients who healed. Forty seven per cent of the unhealed patients also failed to heal with the 40 mg dose. These patients had similar levels of acid exposure before treatment to those who healed, but had greater acid exposure while receiving treatment, particularly at night when supine.
CONCLUSIONS: Patients with severe ulcerative oesophagitis who are refractory to omeprazole have greater oesophageal acid exposure while receiving treatment than responding patients. This is due to a reduced responsiveness to acid suppression, and is likely to be an important factor underlying the failure of the oesophagitis to heal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707107      PMCID: PMC1383143          DOI: 10.1136/gut.38.5.649

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  35 in total

1.  Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study.

Authors:  S J Sontag; B I Hirschowitz; S Holt; M G Robinson; J Behar; M M Berenson; A McCullough; A F Ippoliti; J E Richter; G Ahtaridis
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

2.  Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer, or pernicious anaemia.

Authors:  S Lanzon-Miller; R E Pounder; M R Hamilton; N A Chronos; S Ball; J E Mercieca; M Olausson; C Cederberg
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

3.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

Authors:  D J Hetzel; J Dent; W D Reed; F M Narielvala; M Mackinnon; J H McCarthy; B Mitchell; B R Beveridge; B H Laurence; G G Gibson
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

4.  Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study.

Authors:  S Sandmark; R Carlsson; O Fausa; L Lundell
Journal:  Scand J Gastroenterol       Date:  1988-06       Impact factor: 2.423

5.  Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.

Authors:  E C Klinkenberg-Knol; S G Meuwissen
Journal:  Aliment Pharmacol Ther       Date:  1990-10       Impact factor: 8.171

6.  A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis.

Authors:  B I Hirschowitz
Journal:  Gastroenterology       Date:  1991-11       Impact factor: 22.682

7.  Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis.

Authors:  G Vantrappen; L Rutgeerts; P Schurmans; J L Coenegrachts
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

8.  Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists.

Authors:  H Koop; J Hotz; G Pommer; M Klein; R Arnold
Journal:  Aliment Pharmacol Ther       Date:  1990-12       Impact factor: 8.171

9.  The significance of the gastric secretory state in gastroesophageal reflux disease.

Authors:  A P Barlow; T R DeMeester; C S Ball; E P Eypasch
Journal:  Arch Surg       Date:  1989-08

10.  Bile acid concentrations in the refluxate of patients with reflux oesophagitis.

Authors:  D C Gotley; A P Morgan; M J Cooper
Journal:  Br J Surg       Date:  1988-06       Impact factor: 6.939

View more
  24 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Anti-relaxation therapy in GORD.

Authors:  J Tack; D Sifrim
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 3.  Management of reflux disease.

Authors:  J Dent
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

4.  Gastroesophageal Reflux Disease.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1998-12

Review 5.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.

Authors:  Charles J Lightdale; Colleen Schmitt; Clara Hwang; Bernard Hamelin
Journal:  Dig Dis Sci       Date:  2006-06-14       Impact factor: 3.199

7.  A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.

Authors:  Colleen Schmitt; Charles J Lightdale; Clara Hwang; Bernard Hamelin
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

8.  Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis.

Authors:  Hsin Cheng; Yu-Ching Tsai; Wei-Ying Chen; Wei-Lun Chang; Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

9.  Dental erosions and other extra-oesophageal symptoms of gastro-oesophageal reflux disease: Evidence, treatment response and areas of uncertainty.

Authors:  Ans Pauwels
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

10.  Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.

Authors:  G H Koek; D Sifrim; T Lerut; J Janssens; J Tack
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.